T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.48B |
| 2 |
Kenvue
KVUE
|
+$1.5B |
| 3 |
Halliburton
HAL
|
+$1.12B |
| 4 |
Boeing
BA
|
+$950M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$920M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.64B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.66B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.56B |
| 5 |
Amazon
AMZN
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.76% |
| 2 | Healthcare | 16.83% |
| 3 | Financials | 10.91% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Vaxcyte
PCVX
$8.93B
| $123M | 0.02% |
2,417,652
+225,270
| +10% | +$11.1M |
|
477
CoStar Group
CSGP
$12.5B
| $122M | 0.02% |
1,588,978
-1,254,986
| -44% | -$104M |
|
478
Eaton
ETN
$177B
| $122M | 0.02% |
572,673
-5,152,317
| -90% | -$1.11B |
|
|
AIV
479
Aimco
AIV
$378M
| $121M | 0.02% |
17,759,083
-187,733
| -1% | -$1.49M |
|
480
MoonLake Immunotherapeutics
MLTX
$1.41B
| $121M | 0.02% |
2,117,868
+174,812
| +9% | +$9.65M |
|
481
East-West Bancorp
EWBC
$18.6B
| $121M | 0.02% |
2,288,705
-27,020
| -1% | -$1.52M |
|
|
CERE
482
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $120M | 0.02% |
5,503,498
+278,698
| +5% | +$6.97M |
|
483
Acadia Realty Trust
AKR
$2.86B
| $118M | 0.02% |
8,236,964
+1,113,166
| +16% | +$16.9M |
|
484
HDFC Bank
HDB
$119B
| $118M | 0.02% |
4,004,542
-65,738
| -2% | -$2.14M |
|
485
KT
KT
$9.09B
| $118M | 0.02% |
9,207,907
+1,395,897
| +18% | +$16.8M |
|
486
Apple Hospitality REIT
APLE
$3.75B
| $117M | 0.02% |
7,621,524
+1,828,643
| +32% | +$28M |
|
487
Snap
SNAP
$8.81B
| $115M | 0.02% |
12,959,020
+11,454,136
| +761% | +$120M |
|
|
CHX
488
DELISTED
ChampionX
CHX
| $115M | 0.02% |
3,241,209
+67,727
| +2% | +$2.41M |
|
|
EXAS
489
DELISTED
Exact Sciences
EXAS
| $115M | 0.02% |
1,683,334
-498,552
| -23% | -$42.3M |
|
490
Ares Management
ARES
$32.6B
| $115M | 0.02% |
1,114,998
-64,761
| -5% | -$6.55M |
|
491
Idexx Laboratories
IDXX
$44B
| $114M | 0.02% |
260,923
+52,903
| +25% | +$26.4M |
|
492
Roblox
RBLX
$25.9B
| $113M | 0.02% |
3,908,050
-3,493,274
| -47% | -$116M |
|
493
Ultragenyx Pharmaceutical
RARE
$2.62B
| $113M | 0.02% |
3,160,160
-454,832
| -13% | -$18M |
|
494
Camden Property Trust
CPT
$11.1B
| $112M | 0.02% |
1,187,525
+45,225
| +4% | +$4.81M |
|
495
ScottsMiracle-Gro
SMG
$3.57B
| $112M | 0.02% |
2,158,069
-96,683
| -4% | -$5.6M |
|
496
10x Genomics
TXG
$7.58B
| $111M | 0.02% |
2,687,451
+30,127
| +1% | +$1.57M |
|
497
News Corp Class B
NWS
$17.7B
| $111M | 0.02% |
5,310,922
+125,225
| +2% | +$2.59M |
|
498
Alexandria Real Estate Equities
ARE
$8.31B
| $110M | 0.02% |
1,103,473
-119,925
| -10% | -$13.9M |
|
499
Acadia Pharmaceuticals
ACAD
$4.98B
| $109M | 0.02% |
5,230,161
-783,753
| -13% | -$21.3M |
|
500
Paychex
PAYX
$43.1B
| $109M | 0.02% |
941,825
+5,527
| +0.6% | +$666K |
|
Similar funds
T. Rowe Price Associates's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Associates held 2,959 positions worth $682B, down 4.9% from $718B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.7%. T. Rowe Price Associates opened 69 new positions and exited 71, leaving the 2,959-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2023 buy was Maplebear: 6,435,942 shares worth $191M.
- T. Rowe Price Associates added most to SLB Ltd in Q3 2023, an estimated $2.48B increase.
- T. Rowe Price Associates's biggest Q3 2023 reduction was Microsoft, cutting an estimated $2.64B.
- T. Rowe Price Associates fully exited Life Storage, Inc. in Q3 2023, selling an estimated $285M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $682B portfolio in Q3 2023.
- T. Rowe Price Associates opened 69 new positions and closed 71 in Q3 2023.
- T. Rowe Price Associates's portfolio value fell 4.9% quarter-over-quarter to $682B.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.